{
    "clinical_study": {
        "@rank": "78918", 
        "acronym": "OAK", 
        "arm_group": [
            {
                "arm_group_label": "Part A: Formulation Switch", 
                "arm_group_type": "Experimental", 
                "description": "AZD5363 tablet twice daily followed by AZD5363 capsule twice daily on an intermittent regimen (4 days on, 3 days off)."
            }, 
            {
                "arm_group_label": "Part B: Food effect", 
                "arm_group_type": "Experimental", 
                "description": "AZD5363 tablet twice daily on an intermittent regimen (4 days on, 3 days off) with/without food on one occasion"
            }
        ], 
        "brief_summary": {
            "textblock": "Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic\n      Exposure, Safety and Tolerability"
        }, 
        "brief_title": "Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability.", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Advanced Solid Malignancy,", 
            "Safety and Tolerability,", 
            "Pharmacokinetics, Pharmacodynamics,", 
            "Tumour Response,"
        ], 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This study is designed to investigate the safety, tolerability and pharmacokinetics of a new\n      drug, AZD5363, in patients with advanced cancer . This study will investigate how the body\n      handles AZD5363 (ie, how quickly the body absorbs and removes the drug), the comparison of a\n      capsule and a tablet formulation and the effect of food on AZD5363 tablet formulation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged at least 18 years. -The presence of a solid, malignant tumour, excluding\n             lymphoma, that is resistance to standard therapies or for which no standard therapies\n             exist. - The presence of at least one lesion that can be accurately assessed at\n             baseline by CT, MRI or plain X-ray and is suitable for repeated assessment.  -\n             Estimated life expectancy of more than 12 weeks\n\n        Exclusion Criteria:\n\n          -  Clinically significant abnormalities of glucose metabolism. - Spinal cord compression\n             or brain metastases unless asymptomatic, treated and stable (not requiring steroids).\n             - Evidence of severe or uncontrolled systemic diseases, including active bleeding\n             diatheses or active infections including hepatitis B, C and HIV. - Evidence of\n             clinically significant cardiac abnormalities, uncontrolled hypotension, left\n             ventricular ejection fraction below the lower limit of normal for the site or\n             experience of significant cardiac interventional procedures. - A bad reaction to\n             AZD5363 or any drugs similar to it in structure or class."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01895946", 
            "org_study_id": "D3610C00007"
        }, 
        "intervention": [
            {
                "arm_group_label": "Part A: Formulation Switch", 
                "description": "Oral AZD5363 twice daily, 4 days on 3 days off:  tablet formulation for one week, followed by two weeks with capsule formulation.", 
                "intervention_name": "AZD5363", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part B: Food effect", 
                "description": "Oral AZD5363 twice daily, 4 days on 3 days off, tablet formulation. On day 4 AZD5363 tablet without food. On day 11 AZD5363 tablet with food.", 
                "intervention_name": "AZD5363", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Advanced solid malignancy, AZD5363,", 
            "food effect,", 
            "formulation comparison"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Surrey", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Netherlands", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Open-Label, Multicentre Study to Compare Two Dosage Formulations of AZD5363 and to Establish the Effect of Food on the Pharmacokinetic Exposure, Safety and Tolerability of AZD5363 in Patients With Advanced Solid Malignancies", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "AstraZeneca Clinical Study Information", 
            "phone": "800-236-9933"
        }, 
        "overall_official": [
            {
                "affiliation": "AstraZeneca", 
                "last_name": "Paul Stockman, MBChB, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Institute of Cancer Research, United Kingdom", 
                "last_name": "Udai Banerji, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Part A: AZD5363 PK (plasma concentration) of tablet and capsule formulations", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 11"
            }, 
            {
                "measure": "Part B: PK (plasma concentration) of a AZD5363 tablet formulation with food", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 11"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01895946"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Part A: PK for AZD5363 new tablet formulation (maximum plasma concentration at steady state)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 11"
            }, 
            {
                "measure": "Part B: Within-patient comparison of steady state exposure of AZD5363 tablet with/without food (plasma concentrations Css max and Css min)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 11"
            }, 
            {
                "measure": "Part A and B: Safety and tolerability of AZD5363 in terms of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Screening to 28 days after study drug discontinuation"
            }, 
            {
                "measure": "Parts A,B: Obtaining of a preliminary assessment of anti-tumour activity of AZD5363 via use of Response Evaluation Criteria in Sold Tumours (RECIST) version", 
                "safety_issue": "No", 
                "time_frame": "6 weekly intervals until discontinuation of study therapy"
            }, 
            {
                "measure": "Part B: Safety and tolerability of AZD5363 tablet in terms of adverse events and serious adverse events, death, changes from baseline of laboratory data (clinical chemistry, haematology, urinalysis), vital signs, and electrocardiogram (ECG) parameters", 
                "safety_issue": "Yes", 
                "time_frame": "Screening to 28 days after study drug discontinuation"
            }, 
            {
                "measure": "Part A: PK for AZD5363 new tablet formulation (time to Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 11"
            }, 
            {
                "measure": "Part A: PK for AZD5363 new tablet formulation (area under plasma concentration time curve at steady state)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 11"
            }, 
            {
                "measure": "Part A: PK for AZD5363 new tablet formulation (oral plasma clearance at steady state)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 11"
            }, 
            {
                "measure": "Part B: Within-patient comparison of steady state exposure of AZD5363 tablet with/ without food (time to Css max)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 11"
            }, 
            {
                "measure": "Part B: Within-patient comparison of steady state exposure of AZD5363 tablet with/without food (area under the plasma concentration-time curve at steady state)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 11"
            }, 
            {
                "measure": "Part A and B: Safety and tolerability of AZD5363 in terms of death", 
                "safety_issue": "Yes", 
                "time_frame": "Screening to 28 days after study drug discontinuation"
            }, 
            {
                "measure": "Part A and B: Safety and tolerability of AZD5363 in terms of changes from baseline of laboratory data", 
                "safety_issue": "Yes", 
                "time_frame": "Screening to 28 days after study drug discontinuation"
            }, 
            {
                "measure": "Part A and B: Safety and tolerability of AZD5363 in terms of changes in electrocardiogram (ECG) parameters", 
                "safety_issue": "Yes", 
                "time_frame": "Screening to 28 days after study drug discontinuation"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}